Regulatory Approvals

FDA Approves Brepocitinib as First Oral Drug for Dermatomyositis

By

Regulatory Approvals — FDA Approves Brepocitinib as First Oral Drug for Dermatomyositis  The American Journal of Managed Care

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 28, 2026.

By

Related Post

Regulatory Approvals

FDA approves updated Covid-19 vaccines for dominant XFG variant

Regulatory Approvals

US FDA approves Gilead’s once-daily combination pill for HIV treatment

Regulatory Approvals

FDA approves pancreatic cancer pill as Tyler patient sees results in similar clinical trial

Financial News For All

Regulation

Paramount Antitrust Suit Should Go To Supreme Court, Iowa AG Insists

Regulation

SEC: 38 Entities Feigned Legitimacy as U.S. Advisers Through False Filings to Lure Retail Investors

Regulation

EPA Administrator Lee Zeldin Names New Director to Advance Long Island Sound Restoration

Regulation

EPA Announces Two Major Scientific Advancements to Further Eliminate Animal Testing, Raise the Scientific Bar for Chemical Reviews